Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy
Yasir J. Sepah, V. Diana, Marina Mesquida, Bann-mo Day, Steven Blotner, Rubbia Afridi, Muhammad Sohail Halim, Kyu Hong, Eric Wakshull, Sascha Fauser, Ivaylo Stoilov, Quan Dong Nguyen, Quan Dong Nguyen, Prema Abraham, D. Virgil Alfaro, Andrew N. Antoszyk, M V Antworth, Betsy Baker, C. Baker, Mark Balles, M. Balles, William C. Bridges, David M. Brown, Brandon Busbee, Miguel Busquets, Catherine B. Chan, N. A. Chaudhry, S-N Chen, John Christoforidis, Thomas A. Ciulla, W. Lloyd Clark, Timothy P. Cleland, Thomas B. Connor, A. Daccache, Amr Dessouki, Kenneth R. Diddie, Bernard H. Doft, Robert N. Dreyer, David Faber, Leonard Feiner, Robert Feldman, Philip J. Ferrone, Gregory M. Fox, Scott Foxman, R. E. P. Frenkel, Anne E. Fung, RP Gallemore, T. Ghuman, Víctor H. González, Alan Gordon, Carmelina Gordon, Sunil Gupta, Seenu M. Hariprasad, Jeffrey S. Heier, Allen C. Ho, David R. Holmes, Jingang Huang, Jean‐Pierre Hubschman, Henry L. Hudson, Darmakusuma Ie, Robert N. Johnson, Richard S. Katz, Szilárd Kiss, John W. Kitchens, Gregg T. Kokame, Eugene S. Lit, M. Liu, J. Luu, Mathew W. MacCumber, Steven A. Madreperla, Dennis M. Marcus, Adam Martidis, Jean Martínez, Mark Michels, Daniel M. Miller, Lawrence S. Morse, Ma'an Nasir, Quan Dong Nguyen, Scott R. J. Oliver, Kim Rose Olsen, Sunil Patel, Peter R. Pavan, Joel Pearlman, Jonathan L. Prenner, Carl D. Regillo, Elias Reichel, Robert H. Rosa, Stephen Rose, Srinivas R. Sadda, Michael Samuel, Lawrence J. Singerman, Michael Singer, Rishi P. Singh, Glenn Stoller, Iván J. Suñer, Ali Tabassian, Barry Taney, Allen B. Thach, M.A. Thomas, Michael Tolentino
Abstract
BACKGROUND: This analysis evaluated aqueous humour (AH) interleukin (IL)-6 concentrations and the association between AH IL-6 and visual outcomes in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DMO) receiving anti-vascular endothelial growth factor (VEGF) monotherapy. METHODS: Post hoc analysis of the multicentre, double-masked, randomised HARBOR (NCT00891735) and READ-3 (NCT01077401) trials. HARBOR enrolled treatment-naïve nAMD patients. READ-3 enrolled treatment-naïve/previously treated DMO patients. HARBOR patients received ranibizumab 0.5 or 2.0 mg monthly or as needed; AH samples were collected at month 2, after two previous intravitreal injections. READ-3 patients received ranibizumab 0.5 or 2.0 mg as needed; AH samples were collected at baseline and months 3, 6, 9, and 12. MAIN OUTCOME MEASURE: association between AH IL-6 concentrations and month 24 best-corrected visual acuity (BCVA). RESULTS: In both trials (HARBOR, N = 36; READ-3, N = 137), patients with higher AH IL-6 concentrations had worse visual outcomes. HARBOR patients with low AH IL-6 concentrations at month 2 had a mean (95% CI) BCVA change at month 24 of +2.9 (-2.6, 8.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of -9.0 (-22.7, 4.7) letters. READ-3 patients with low AH concentrations at baseline had a mean (95% CI) BCVA change at month 12 of +9.3 (7.4, 11.3) letters, whereas patients with high AH concentrations had a mean (95% CI) BCVA change of +5.6 (2.2, 9.1) letters. CONCLUSIONS: Higher IL-6 AH concentrations may predict suboptimal visual responses to anti-VEGF monotherapy in patients with nAMD/DMO.